Cancer anti-angiogenic therapy

Area of Science:

• Oncology
• Vascular Biology
• Drug Delivery Systems

Background:

• Tumor angiogenesis, the formation of new blood vessels, is crucial for tumor growth and metastasis.
• Traditional anti-angiogenic therapies inhibit vessel formation but may not cause tumor regression.
• Cytotoxic chemotherapy faces challenges including low specificity and severe side effects.

Purpose of the Study:

• To review traditional anti-angiogenic therapy and introduce anti-neovascular therapy (ANET).
• To discuss the potential of ANET in cancer treatment, including its mechanisms and advantages.
• To explore related approaches like metronomic chemotherapy and anti-angiogenic photodynamic therapy (PDT).

Main Methods:

• Review of existing literature on anti-angiogenic strategies and ANET.
• Discussion of drug delivery systems (DDS) for targeted delivery of anti-cancer agents.
• Analysis of metronomic chemotherapy and anti-angiogenic photodynamic therapy (PDT) applications.

Main Results:

• ANET inflicts indirect damage on tumor cells by targeting proliferating neovascular endothelial cells.
• ANET may offer reduced side effects compared to traditional chemotherapy due to targeted delivery.
• Neovascular endothelial cells are unlikely to develop drug resistance, a key advantage of ANET.

Conclusions:

• ANET presents a promising strategy for cancer therapy by targeting tumor vasculature.
• Combining ANET with DDS technology or metronomic dosing could enhance efficacy and reduce toxicity.
• Anti-angiogenic PDT is a clinically relevant example of targeting aberrant angiogenesis.